Thalomid and Hydrea drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Thalomid (thalidomide) and Hydrea (hydroxyurea). Common drug interactions include disease progression among females and acute myeloid leukaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Thalomid and Hydrea. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Thalomid?

Thalomid has active ingredients of thalidomide. It is often used in multiple myeloma. eHealthMe is studying from 38,099 Thalomid users. Check the latest studies of Thalomid.

What is Hydrea?

Hydrea has active ingredients of hydroxyurea. It is often used in polycythemia vera. eHealthMe is studying from 9,083 Hydrea users. Check the latest studies of Hydrea.

On Aug, 09, 2026

35 people who take Thalomid and Hydrea together, and have interactions are studied.

What are the common drug interactions of Thalomid and Hydrea, by gender? *:

female:

Disease progression
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Platelet count increased
Hypoaesthesia (reduced sense of touch or sensation)
Pain in extremity
Abdominal distension
Abdominal pain
Asthenia (weakness)
Blood potassium increased
Cardio-respiratory arrest (sudden dysfunction of heart and lungs)

male:

Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Anaemia (lack of blood)
Cardiac disorder
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Gait disturbance
Hypoaesthesia (reduced sense of touch or sensation)
Lung disorder (lung disease)
Pain in extremity
Peripheral vascular disorder
Death

What are the common drug interactions of Thalomid and Hydrea, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Platelet count increased
Anaemia (lack of blood)
Disease progression
Drug ineffective
Myelofibrosis (a disease in which abnormal blood cells and fibres build up inside the bone marrow)
Septic shock (shock due to blood infection)
Thrombocytopenia (decrease of platelets in blood)

60+:

Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
Cardiac failure congestive
Cardiac disorder
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Gait disturbance
Lung disorder (lung disease)
Pain in extremity
Peripheral vascular disorder
Abdominal pain
Death

What are the existing conditions these people have? *

Primary Myelofibrosis (primary disorder of the bone marrow): 13 people, 37.14%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 7 people, 20.00%
Leukocytosis (increased white blood cells): 3 people, 8.57%
Thrombocytopenia (decrease of platelets in blood): 2 people, 5.71%
Iron Overload: 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Thalomid and Hydrea?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously